Next Generation Ocular Drug Delivery Platforms

Next Generation Ocular Drug Delivery Platforms
The human eye measures approximately one inch in diameter, but traversing that blink-of-an-eye distance to achieve safe, effective and stable delivery of ophthalmology drugs via minimally or non-invasive medical devices to treat major eye diseases has taken more than 40 years to accomplish.

Is the wait for a Holy Grail product in ophthalmology medical technology soon to be over for researchers, patients and stakeholders?

Despite these decades of research, there are only four approved intraocular sustained release drug delivery products approved for use and approved globally or specific to Europe. Vitrasert® 1995 ganciclovir 4.5mg. Retisert® 2005, fluocinolone acetonide 0.59mg. Ozurdex® dexamethasone 0.7mg. Iluvien® fluocinolone acetonide 190μg.

The future for sustained-release ocular drug delivery lies in reducing the treatment burden by commercializing innovations in delivery technology, biologics delivery, targeting gene therapy to the appropriate cell types, and combining effective small-molecule therapeutics with the appropriate drug delivery system. Patient compliance will be a key driver in the pursuit of ocular drug delivery; however, a demonstration of improved efficacy for a new product will practically be essential if delivering competitive advantage is to be achieved.

Read the full report below:

SHARE THIS ARTICLE WITH YOUR COLLEAGUES:

RECOMMENDED FOR YOU

MicrosoftTeams-image (62)

Oyster Point Ramps Up for Tyrvaya, First Dry Eye Nasal Spray

Pod 306 Bill McPhee - Thumb

Faster, Better, Smarter, Cheaper With MacuLogix’s Bill McPhee

the oral retina drugs are coming

Six Oral Retina Drug Development Programs to Watch

OPUS Genetics

Opus Genetics: RD Fund’s First Spinout to Advance Gene Therapies for Inherited Retinal Diseases

Pod 304 - Karpecki - Gertner - Thumbnail

DIY Commercialization, with Olympic Ophthalmics’ Michael Gertner, MD

MicrosoftTeams-image (139)

OIS Glaucoma Showcase Take-Home: Glaucoma Market Poised For Growth

About The Author

Tom Salemi

Tom serves as Content Director for Healthegy, joining the company in 2014, to create and manage a new line of podcasts, publications and other editorial products. At Healthegy, Tom hosts the OIS Podcast and MedtechTalk, contributes to the Engage and Eye on Innovation newsletters and assists in the agenda development of new and existing conferences.

SUBSCRIBE TO OUR NEWSLETTER

Get The Latest News In Opthalmologic Innovation To Your Inbox.

We respect your privacy and will never send you spam.

Something went wrong. Please check your entries and try again.

SUBSCRIBE TO OIS WEEKLY

Get our monthly newsletter about the latest in opthalmologic innovation.

We respect your privacy and will never send you spam.

Something went wrong. Please check your entries and try again.

STAY CONNECTED

PODCASTS